Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
GV20 received an upfront payment and is eligible for additional milestone payments
The fresh capital will propel Cordance into its first-in-human clinical trial
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Consolidated revenue from operations stood at Rs. 111.05 crore
Total income for the period stood at Rs. 7101.28 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Subscribe To Our Newsletter & Stay Updated
